HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy

Clinical Cancer Research

Volumn 18, Issue 17, 2012, Pages 4691-4701

  Lin, Kuen Tyng ^a   Wang, Yi Wei ^a   Chen, Chiung Tong ^c   Ho, Chun Ming ^a,b,d   Su, Wen Hui ^e   Jou, Yuh Shan ^a,b  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b INSTITUTE OF INFORMATION SCIENCE   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^e CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN P21; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CANCER; LUNG CANCER; METASTASIS; MMP GERNE; PKC GENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; STOMACH CANCER; UPREGULATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; CURCUMIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; MICE; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN KINASE C; TAMOXIFEN;

EID: 84865740818     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0633     Document Type: Article

References (50)

1. WHO. World Health Organization: cancer. 2010. [cited2010 Mar 03]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/.
2. Brena RM, Costello JF. Genome-epigenome interactions in cancer. Hum Mol Genet 2007;16:R96-105.
3. Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009;15:3918-26.
4. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets?Cancer Lett 2009;277:8-21.
5. Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 2012;31:537-51.
6. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50.
7. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010;19:1049-66.
8. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459-68.
9. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31.
10. Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodinerefractory thyroid carcinoma. J Clin Endocrinol Metab 2009;94:164-70.
11. Gahr S, Peter G, Wissniowski TT, Hahn EG, Herold C, Ocker M. The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines. Oncol Rep 2008;20:1249-56.
12. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009;15:3970-7.
13. Tatebe H, Shimizu M, Shirakami Y, Sakai H, Yasuda Y, Tsurumi H, et al. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells. Cancer Lett 2009;285:210-7.
14. Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H. Invasion and metastasis in pancreatic cancer. Mol Cancer 2003;2:14.
15. Kramer OH, Gottlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 2001;12:294-300.
16. Ali AS, Ali S, El-Rayes BF, Philip PA, Sarkar FH. Exploitation of protein kinase C: a useful target for cancer therapy. Cancer Treat Rev 2009;35:1-8.
17. Podar K, Raab MS, Chauhan D, Anderson KC. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs 2007;16:1693-707.
18. Bosco R, Melloni E, Celeghini C, Rimondi E, Vaccarezza M, Zauli G. Fine tuning of protein kinaseC(PKC) isoformsin cancer: shortening the distance from the laboratory to the bedside. Mini Rev Med Chem 2011;11:185-99.
19. Reyland ME. Protein kinase C isoforms: multi-functional regulators of cell life and death. Front Biosci 2009;14:2386-99.
20. Chen CF, Hsu EC, Lin KT, Tu PH, Chang HW, Lin CH, et al. Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma. Hepatology 2010;52:1690-701.
21. Lin KT, Yeh SH, Chen DS, Chen PJ, Jou YS. Epigenetic activation of alpha4, beta2 and beta6 integrins involved in cell migration in trichostatin A-treated Hep3B cells. J Biomed Sci 2005;12:803-13.
22. Shin DH, Kim JH, Jung YJ, Kim KE, Jeong JM, Chun YS, et al. Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 2007;255:107-16.
23. Wang H, Xiao L, Kazanietz MG. p23/Tmp21 associates with protein kinase C delta (PKCdelta) and modulates its apoptotic function. J Biol Chem 2011;286:15821-31.
24. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004;9:63-79.
25. Parker PJ, Murray-Rust J. PKC at a glance. J Cell Sci 2004;117:131-2.
26. Reuben PM, Cheung HS. Regulation of matrix metalloproteinase (MMP) gene expression by protein kinases. Front Biosci 2006;11:1199-215.
27. zumBuschenfelde CM, Wagner M, Lutzny G, Oelsner M, Feuerstacke Y, Decker T, et al. Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia 2010;24:141-52.
28. Richards TS, Dunn CA, Carter WG, Usui ML, Olerud JE, Lampe PD. Protein kinase C spatially and temporally regulates gap junctional communication during human wound repair via phosphorylation of connexin43 on serine368. J Cell Biol 2004;167:555-62.
29. Guo K, Liu Y, Zhou H, Dai Z, Zhang J, Sun R, et al. Involvement of protein kinase C beta-extracellular signal-regulating kinase 1/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion. Cancer Sci 2008;99:486-96.
30. Gururajan M, Dasu T, Shahidain S, Jennings CD, Robertson DA, Rangnekar VM, et al. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol 2007;178:111-21.
31. Zeisig R, Ruckerl D, Fichtner I. Reduction of tamoxifen resistance in human breast carcinomas by tamoxifen-containing liposomes in vivo. Anticancer Drugs 2004;15:707-14.
32. Gatenby RA. A change of strategy in the war on cancer. Nature 2009;459:508-9.
33. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-52.
34. Kim SO, Choi BT, Choi IW, Cheong J, Kim GY, Kwon TK, et al. Anti-invasive activity of histone deacetylase inhibitors via the induction of Egr-1 and the modulation of tight junction-related proteins in human hepatocarcinoma cells. BMB Rep 2009;42:655-60.
35. Kim NH, Kim SN, Kim YK. Involvement of HDAC1 in E-cadherin expression in prostate cancer cells: its implication for cell motility and invasion. Biochem Biophys Res Commun 2011;404:915-21.
36. Kuwajima A, Iwashita J, Murata J, Abe T. The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel. Anticancer Res 2007;27:4163-9.
37. Wilson AJ, Gibson PR. Short-chain fatty acids promote the migration of colonic epithelial cells in vitro. Gastroenterology 1997;113:487-96.
38. Mori T, Kim J, Yamano T, Takeuchi H, Huang S, Umetani N, et al. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 2005;65:1800-7.
39. Uchida H, Maruyama T, Ono M, Ohta K, Kajitani T, Masuda H, et al. Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology 2007;148:896-902.
40. Pulukuri SM, Gorantla B, Rao JS. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J Biol Chem 2007;282:35594-603.
41. Castro-Galache MD, Menendez-Gutierrez MP, Carrasco Garcia E, Garcia-Morales P, Martinez-Lacaci I, Saceda M, et al. Protein kinase C-alpha antagonizes apoptosis induction by histone deacetylase inhibitors in multidrug resistant leukaemia cells. Int J Biochem Cell Biol 2007;39:1877-85.
42. Bodo J, Sedlak J, Maciejewski JP, Almasan A, Hsi ED. HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. Apoptosis 2011;16:914-23.
43. Yamamoto N, Yang M, Jiang P, Xu M, Tsuchiya H, Tomita K, et al. Determination of clonality of metastasis by cell-specific color-coded fluorescent-protein imaging. Cancer Res 2003;63:7785-90.
44. Ansieau S, Hinkal G, Thomas C, Bastid J, Puisieux A. Early origin of cancer metastases: dissemination and evolution of premalignant cells. Cell Cycle 2008;7:3659-63.
45. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008;269:199-225.
46. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001;6:469-77.
47. Giommarelli C, Zuco V, Favini E, Pisano C, Dal Piaz F, De Tommasi N, et al. The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell Mol Life Sci 2010;67:995-1004.
48. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011;104:1828-35.
49. Liu Y, Dargusch R, Maher P, Schubert D. A broadly neuroprotective derivative of curcumin. J Neurochem 2008;105:1336-45.
50. Ingle JN. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 2008;112:695-9.